Founded in 2004 and headquartered in Portland, Oregon, AMES Technology, Inc. is dedicated to advancing sub-acute clinical trials in the United States. The company's core mission is to enhance motor and sensory rehabilitation through innovative medical devices. Their flagship product, the FDA-cleared AMES Rehabilitation Therapy Medical Device, offers simultaneous assisted movement and sensory stimulation for patients with central nervous system injuries. AMES Technology operates trial sites in Spokane, San Francisco, Atlanta, and Chicago, focusing on conditions like stroke, incomplete spinal cord injury, and acquired brain injury.

AMES Technology has garnered attention for its pioneering approach to rehabilitation therapy. Several notable clinicians and researchers are affiliated with the company, contributing to its development and clinical trials. The company has achieved significant milestones, including the widespread clinical use of its AMES units across the United States. These achievements have positioned AMES Technology as a key player in the rehabilitation sector, making a substantial impact on improving patient outcomes and advancing medical research in neurorehabilitation.